Supplemental material
Journal of Medical Economics
Volume 22, 2019 - Issue 8
Open access
3,931
Views
4
CrossRef citations to date
0
Altmetric
Oncology
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy
Evangelos Terposa Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Correspondence[email protected]
, Aurelien Jamotteb Global Health Economics, Amgen (Europe) GmbH, Rotkreuz, Switzerland;
, Alexandra Christodoulopoulouc Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA;
, Marco Campionib Global Health Economics, Amgen (Europe) GmbH, Rotkreuz, Switzerland;
, Debajyoti Bhowmikc Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA;
, Lisa Kennedyd Epiphany, Los Angeles, CA, USA;
& Wolfgang Willenbachere Department of Internal Medicine V, Innsbruck University Hospital & Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria
show all
Pages 766-776
|
Received 21 Feb 2019, Accepted 05 Apr 2019, Published online: 29 Apr 2019
Related Research Data
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America
Source:
Informa UK Limited
Cost of skeletal complications from bone metastases in six European countries.
Source:
Informa Healthcare
Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.
Source:
Taylor & Francis
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Source:
Elsevier BV
Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
Source:
Informa UK Limited
Generalized cost-effectiveness analysis for national-level priority-setting in the health sector
Source:
Springer Science and Business Media LLC
Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report
Source:
International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study
Source:
Informa Healthcare
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.
Source:
Informa UK Limited
Guidelines for Economic Evaluations in Italy: Recommendations from the Italian Group of Pharmacoeconomic Studies
Source:
Springer Science and Business Media LLC
Guidelines zur gesundheitsökonomischen Evaluation Konsenspapier
Source:
Springer Science and Business Media LLC
Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer
Source:
Informa UK Limited
Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
Source:
National Institute for Health Research
The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium
Source:
Informa UK Limited
Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases
Source:
Springer Science and Business Media LLC
Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Source:
Informa UK Limited
Metastatic bone pain: treatment options with an emphasis on bisphosphonates
Source:
Springer Science and Business Media LLC
Health state utilities for skeletal-related events secondary to bone metastases
Source:
Springer Verlag (Germany)
Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Source:
Elsevier BV
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
Source:
American Society of Clinical Oncology (ASCO)
Role of the RANK/RANKL Pathway in Multiple Myeloma.
Source:
American Association for Cancer Research (AACR)
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.